Unnamed: 0,title,date,stock,sentiment
468515.0,"Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $32",2020-06-01 11:44:00-04:00,EXEL,neutral
468516.0,Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.,2020-05-14 11:18:00-04:00,EXEL,negative
468517.0,"SunTrust Robinson Humphrey Maintains Buy on Exelixis, Raises Price Target to $40",2020-05-14 11:05:00-04:00,EXEL,neutral
468518.0,Exelixis Reports Results From COSMIC-021 Trial Of Cabozantinib In Combo With Atezolizumab In Multiple Advanced Solid Tumor Types,2020-05-13 17:08:00-04:00,EXEL,neutral
468519.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,EXEL,neutral
468520.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,EXEL,neutral
468521.0,"BMO Capital Maintains Market Perform on Exelixis, Raises Price Target to $27",2020-05-06 11:19:00-04:00,EXEL,neutral
468522.0,"Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $21",2020-05-06 08:47:00-04:00,EXEL,neutral
468523.0,"Exelixis Q1 Adj. EPS $0.190 Beats $0.130 Estimate, Sales $226.900M Beat $214.940M Estimate",2020-05-05 16:27:00-04:00,EXEL,neutral
468524.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,EXEL,positive
468525.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,EXEL,neutral
468526.0,"Cramer Weighs In On Cracker Barrel, UPS And More",2020-05-01 08:01:00-04:00,EXEL,neutral
468527.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,EXEL,neutral
468528.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,EXEL,neutral
468529.0,Stocks That Hit 52-Week Highs On Friday,2020-04-24 10:33:00-04:00,EXEL,neutral
468530.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,EXEL,positive
468531.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,EXEL,neutral
468532.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,EXEL,negative
468533.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-22 10:20:00-04:00,EXEL,neutral
468534.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,EXEL,negative
468535.0,Exelixis shares are trading higher after Oppenheimer maintained an Outperform rating on the company's stock and raised its price target from $25 to $28.,2020-04-21 13:55:00-04:00,EXEL,positive
468536.0,"Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to $28",2020-04-21 08:20:00-04:00,EXEL,neutral
468537.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,EXEL,positive
468538.0,78 Biggest Movers From Yesterday,2020-04-21 04:32:00-04:00,EXEL,neutral
468539.0,Needham Raises Exelixis Inc. Price Target From $28 To $33,2020-04-20 13:36:00-04:00,EXEL,neutral
468540.0,54 Stocks Moving In Monday's Mid-Day Session,2020-04-20 12:43:00-04:00,EXEL,neutral
468541.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,EXEL,neutral
468542.0,Exelixis shares are trading higher after the company announced the results from its Phase 3 CheckMate -9ER Trial met the primary endpoint.,2020-04-20 07:24:00-04:00,EXEL,positive
468543.0,Bristol Myers Squibb And Exelixis Announce Topline Results From Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo In Combination With CABOMETYX In Previously Untreated Advanced Renal Cell Carcinoma; Study Met Primary Endpoint,2020-04-20 07:01:00-04:00,EXEL,positive
468544.0,Exelixis Earlier Announces Partner Takeda Receives Approval In Japan For CABOMETYX Tablets For The Treatment Of Curatively Unresectable Or Metastatic Renal Cell Carcinoma,2020-03-25 08:52:00-04:00,EXEL,positive
468545.0,"The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down",2020-03-25 07:29:00-04:00,EXEL,neutral
468546.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-03-25 07:08:00-04:00,EXEL,neutral
468547.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,EXEL,positive
468548.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,EXEL,neutral
468549.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,EXEL,negative
468550.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,EXEL,positive
468551.0,"Barclays Initiates Coverage On Exelixis with Overweight Rating, Announces $26 Price Target",2020-03-04 05:26:00-05:00,EXEL,negative
468552.0,"Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors",2020-03-02 16:10:00-05:00,EXEL,neutral
468553.0,"Stifel Maintains Hold on Exelixis, Raises Price Target to $23",2020-02-26 10:05:00-05:00,EXEL,neutral
468554.0,"BMO Capital Maintains Market Perform on Exelixis, Raises Price Target to $20",2020-02-26 09:11:00-05:00,EXEL,neutral
468555.0,Exelixis shares are trading lower after the company reported worse-than-expected Q4 sales results. The company also issued FY20 sales guidance below estimates.,2020-02-26 08:22:00-05:00,EXEL,neutral
468556.0,44 Stocks Moving in Wednesday's Pre-Market Session,2020-02-26 07:20:00-05:00,EXEL,neutral
468557.0,14 Stocks Moving In Tuesday's After-Hours Session,2020-02-25 16:48:00-05:00,EXEL,neutral
468558.0,Exelixis shares are trading lower after the company reported worse-than-expected Q4 sales results. The company also issued FY20 sales guidance below estimates.,2020-02-25 16:20:00-05:00,EXEL,neutral
468559.0,Exelixis Sees FY20 Sales $850M-$900M vs $944M Estimate,2020-02-25 16:13:00-05:00,EXEL,neutral
468560.0,"Exelixis Q4 EPS $0.26 Beats $0.16 Estimate, Sales $240.3M Miss $240.52M Estimate",2020-02-25 16:13:00-05:00,EXEL,negative
468561.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,EXEL,negative
468562.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,EXEL,neutral
468563.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,EXEL,negative
468564.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,EXEL,positive
468565.0,Exelixis Highlights Results For Cabozantinib In Combo With Ztezolizumab In Metastatic Castration-Resistant Prostate Cancer,2020-02-10 17:01:00-05:00,EXEL,negative
468566.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,EXEL,neutral
468567.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,EXEL,positive
468568.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,EXEL,neutral
468569.0,Exelixis Partner Takeda Files NDA in Japan for CABOMETYX for Advanced Hepatocellular Carcinoma,2020-01-29 05:09:00-05:00,EXEL,positive
468570.0,Exelixis shares are trading lower after the company announced phase 1/2 clinical trial results from the combination of cabozantinib and nivolumab.,2020-01-24 11:44:00-05:00,EXEL,neutral
468571.0,"Exelixis Reports Results For Combo Of Cabozantinib, Nivolumab With Or Without Ipilimumab In Advanced Hepatocellular Carcinoma",2020-01-24 07:35:00-05:00,EXEL,negative
468572.0,Exelixis shares are trading higher. The stock moved higher following unusual interest in next month's $19 call contract.,2020-01-14 14:38:00-05:00,EXEL,positive
468573.0,Exelixis Option Alert: Fri $19 Calls Sweep (20) near the Ask: 1063 @ $0.7 vs 2183 OI; Earnings 2/11 After Close [est] Ref=$19.31,2020-01-14 13:36:00-05:00,EXEL,positive
468574.0,"Benzinga's Top Upgrades, Downgrades For January 13, 2020",2020-01-13 10:27:00-05:00,EXEL,positive
468575.0,"SunTrust Robinson Humphrey Initiates Coverage On Exelixis with Buy Rating, Announces $31 Price Target",2020-01-13 08:43:00-05:00,EXEL,neutral
468576.0,"Bank of America Reiterates Buy on Exelixis, Lowers Price Target to $21",2020-01-13 07:56:00-05:00,EXEL,negative
468577.0,25 Stocks Moving in Monday's Pre-Market Session,2020-01-13 07:30:00-05:00,EXEL,neutral
468578.0,Exelixis Sees FY 2019 Revenue ~$972M vs $957.49M Est; Q4 Revenue $245M vs $231.02M Est,2020-01-12 16:57:00-05:00,EXEL,neutral
468579.0,Exelixis Announces Anticipated Timelines for Data Readouts From Six Cabozantinib Potentially Label-enabling Clinical Studies and Up to Three New Potential Ind Candidates,2020-01-12 16:53:00-05:00,EXEL,neutral
468580.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-07 07:53:00-05:00,EXEL,neutral
468581.0,Exelixis Further Prostate Cancer Cohort In Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors,2020-01-07 07:31:00-05:00,EXEL,negative
468582.0,Exelixis Reports Collaboration For 3 Phase 3 Combo Trials For Patients With Advanced Solid Tumors,2019-12-19 07:07:00-05:00,EXEL,positive
468583.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,EXEL,positive
468584.0,"Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma",2019-12-13 05:23:00-05:00,EXEL,positive
468585.0,Exelixis shares are trading higher on seemingly no company-specific news.,2019-12-10 15:38:00-05:00,EXEL,neutral
468586.0,Exelixis shares are trading higher. Not seeing any news to justify the price action.,2019-12-04 15:01:00-05:00,EXEL,positive
468587.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,EXEL,negative
468588.0,Exelixis shares are trading higher. Not seeing any news to justify the price action.,2019-11-13 11:07:00-05:00,EXEL,positive
468589.0,Exelixis Partner Ipsen Announces Health Canada Approval Of CABOMETYX Tablets For The Treatment Of Patients With Previously Treated Advanced Hepatocellular Carcinoma,2019-11-12 08:02:00-05:00,EXEL,positive
468590.0,Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy,2019-11-08 04:23:00-05:00,EXEL,positive
468591.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,EXEL,negative
468592.0,Exelixis shares are trading lower despite reporting strong Q3 earnings beat.,2019-10-31 10:21:00-04:00,EXEL,negative
468593.0,"Exelixis Reported Yesterday Q3 EPS $0.34 Beats $0.19 Estimate, Sales $271.703M Beat $227.82M Estimate",2019-10-31 10:18:00-04:00,EXEL,neutral
468594.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,EXEL,positive
468595.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,EXEL,negative
468596.0,"Guggenheim Maintains Buy on Exelixis, Lowers Price Target to $25",2019-10-15 08:08:00-04:00,EXEL,negative
468597.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 09, 2019",2019-10-09 14:25:00-04:00,EXEL,positive
468598.0,"BMO Capital Maintains Market Perform on Exelixis, Lowers Price Target to $19",2019-10-08 08:45:00-04:00,EXEL,negative
468599.0,Exelixis shares are trading lower despite no company-specific news. The stock has dropped approximately 15% over the past month.,2019-10-04 15:28:00-04:00,EXEL,positive
468600.0,Exelixis Says Intends To Defend Intellectual Property Rights For CABOMETYX,2019-09-26 17:40:00-04:00,EXEL,positive
468601.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,EXEL,neutral
468602.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,EXEL,negative
468603.0,Pete Najarian Sees Unusual Options Activity In Exelixis,2019-08-30 15:45:00-04:00,EXEL,neutral
468604.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,EXEL,positive
468605.0,Exelixis Option Alert: Sep 20 $24 Calls Sweep (40) near the Ask: 1187 @ $0.6 vs 103 OI; Ref=$21.42,2019-08-16 15:32:00-04:00,EXEL,positive
468606.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,EXEL,negative
468607.0,Exelixis Option Alert: Sep 20 $22 Calls Sweep (31) near the Ask: 1501 @ $1.004 vs 6027 OI; Ref=$21.095,2019-08-16 09:59:00-04:00,EXEL,positive
468608.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,EXEL,negative
468609.0,"Exelixis Reports Exclusive Collaboration, Option, License Deal With Aurigene For Discovery, Development Of Novel Therapies For Cancer",2019-07-31 16:56:00-04:00,EXEL,negative
468610.0,"Exelixis Q2 EPS $0.29 Beats $0.25 Estimate, Sales $240.275M Beat $227.8M Estimate",2019-07-31 16:55:00-04:00,EXEL,neutral
468611.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,EXEL,negative
468612.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,EXEL,negative
468613.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,EXEL,neutral
468614.0,"Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors, Says Adding 4 Cohorts Due to Encouraging Early Data",2019-07-15 07:05:00-04:00,EXEL,positive
468615.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,EXEL,positive
468616.0,26 Stocks Moving In Friday's Pre-Market Session,2019-06-21 08:34:00-04:00,EXEL,neutral
468617.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,EXEL,negative
468618.0,"From 8K Filing Late Thurday: Exelixis Said on June 19 Informed By Genentech, Imspire170, Phase 3 Trial Evaluating Combination of Cobimetinib & Atezolizumab Did Not Meet Primary Endpoint",2019-06-21 06:34:00-04:00,EXEL,neutral
468619.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,EXEL,positive
468620.0,"Exelixis, Iconic Therapeutics Report Exclusive Option, License Deal For Novel Antibody-Drug Conjugate Program",2019-05-16 08:09:00-04:00,EXEL,positive
468621.0,Exelixis' Collaborator Daiichi Sankyo Launches Minnebro Tablets in Japan; Triggers $20MMilestone Payment to Exelixis,2019-05-13 06:07:00-04:00,EXEL,neutral
468622.0,"Jim Cramer Weighs In On Zebra Technologies, Exelixis And More",2019-05-10 07:32:00-04:00,EXEL,neutral
468623.0,Exelixis Initiates Phase 3 Pivotal Trial Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma,2019-05-01 17:47:00-04:00,EXEL,positive
468624.0,"Exelixis Q1 EPS $0.27, Inline, Sales $215.487M Up From $212.346M YoY",2019-05-01 17:36:00-04:00,EXEL,neutral
468625.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,EXEL,neutral
468626.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,EXEL,negative
468627.0,Exelixis Says Checkmate 9ER Recently Completed Enrollment,2019-04-25 14:58:00-04:00,EXEL,neutral
468628.0,"Exelixis' Highlights That Its Partner, Takeda, Filed New Drug Application In Japan For CABOMETYX For Advanced Renal Cell Carcinoma",2019-04-25 06:45:00-04:00,EXEL,positive
468629.0,"Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'",2019-03-18 14:26:00-04:00,EXEL,negative
468630.0,"Benzinga's Top Upgrades, Downgrades For March 16, 2019",2019-03-18 08:53:00-04:00,EXEL,positive
468631.0,Morgan Stanley Upgrades Exelixis to Equal-Weight,2019-03-18 06:23:00-04:00,EXEL,neutral
468632.0,"BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces $23 Price Target",2019-02-22 07:04:00-05:00,EXEL,neutral
468633.0,31 Stocks Moving In Friday's Pre-Market Session,2019-02-15 08:20:00-05:00,EXEL,neutral
468634.0,"Exelixis shares are trading higher after the company reported Q4 EPS of $0.37, beating the $0.24 consensus estimate an sales of $228.6 million beating the $188.76 million estimate; the company said it would initiate Phase 1 clinical development of XL092.",2019-02-13 09:05:00-05:00,EXEL,negative
468635.0,35 Stocks Moving In Wednesday's Pre-Market Session,2019-02-13 08:47:00-05:00,EXEL,neutral
468636.0,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering",2019-02-13 07:49:00-05:00,EXEL,negative
468637.0,7 Stocks Moving In Tuesday's After-Hours Session,2019-02-12 17:12:00-05:00,EXEL,neutral
468638.0,Exelixis Reports Will Initiate Phase 1 Clinical Development Of XL092,2019-02-12 16:43:00-05:00,EXEL,neutral
468639.0,"Exelixis Q4 EPS $0.37 Beats $0.24 Estimate, Sales $228.6M Beat $188.76M Estimate",2019-02-12 16:08:00-05:00,EXEL,neutral
468640.0,Q4 Earnings Preview For Exelixis,2019-02-12 08:16:00-05:00,EXEL,neutral
468641.0,"The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares",2019-02-12 08:04:00-05:00,EXEL,negative
468642.0,"Earnings Scheduled For February 12, 2019",2019-02-12 04:02:00-05:00,EXEL,neutral
468643.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,EXEL,neutral
468644.0,Exelixis Announces FDA Approval Of CABOMETYX Tablets For Previously Treated Hepatocellular Carcinoma,2019-01-14 17:39:00-05:00,EXEL,positive
468645.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-01-13 15:50:00-05:00,EXEL,neutral
468646.0,"Exelixis Announces That Its Partner Daiichi Sankyo Company (DSNKY) Received Approval From The Japanese Ministry of Health For The Marketing Of Esaxerenone Tablets, MINNEBRO As A Treatment For Patients With Hypertension",2019-01-08 06:07:00-05:00,EXEL,positive
468647.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,EXEL,neutral
468648.0,"Exelixis, Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma",2018-12-05 06:24:00-05:00,EXEL,positive
468649.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,EXEL,positive
468650.0,Exelixis' Partner Ipsen Receives EC Approval for CABOMETYX Tablets for Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib,2018-11-15 03:54:00-05:00,EXEL,positive
468651.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,EXEL,neutral
468652.0,64 Stocks Moving In Friday's Mid-Day Session,2018-11-02 12:44:00-04:00,EXEL,neutral
468653.0,34 Stocks Moving In Friday's Pre-Market Session,2018-11-02 08:12:00-04:00,EXEL,neutral
468654.0,"The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug",2018-11-02 08:01:00-04:00,EXEL,negative
468655.0,"Exelixis, Inc. Q3 EPS $0.41 Beats $0.19 Estimate, Sales $225.397M Beat $172.59M Estimate",2018-11-01 17:27:00-04:00,EXEL,neutral
468656.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,EXEL,negative
468657.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,EXEL,negative
468658.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,EXEL,neutral
468659.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,EXEL,neutral
468660.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,EXEL,negative
468661.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,EXEL,negative
468662.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,EXEL,negative
468663.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,EXEL,positive
468664.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,EXEL,neutral
468665.0,Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma,2018-10-22 06:53:00-04:00,EXEL,positive
468666.0,Exelixis Announces Cabozantinib Was Associated With Improved Overall Survival and Progression-free Survival Irrespective of Pd-l1 Expression in Cabosun and Meteor Trials  at ESMO 2018,2018-10-20 16:33:00-04:00,EXEL,positive
468667.0,Exelixis Initiates Phase 3 Pivotal Trial Of Cabozantinib In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy,2018-10-08 08:03:00-04:00,EXEL,negative
468668.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,EXEL,negative
468669.0,Exelixis' Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX Tablets for Previously Treated Hepatocellular Carcinoma,2018-09-21 04:14:00-04:00,EXEL,positive
468670.0,"Exelixis' Partner, Ipsen, Announces Health Canada's Approval For CABOMETYX Tablets In Advanced Renal Cell Carcinoma; Approval Was Based On Improvement In Overall Survival, Progression-Free Survival And Objective Response Rate",2018-09-19 07:36:00-04:00,EXEL,positive
468671.0,"Stocks Which Set New 52-Week Low Yesterday, September 17th",2018-09-18 09:27:00-04:00,EXEL,negative
468672.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,EXEL,positive
468673.0,"Goldman Sachs Initiates Coverage On Exelixis with Neutral Rating, Announces $22 Price Target",2018-09-17 08:24:00-04:00,EXEL,neutral
468674.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,EXEL,negative
468675.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,EXEL,negative
468676.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,EXEL,negative
468677.0,"A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others",2018-09-10 16:10:00-04:00,EXEL,neutral
468678.0,"Morgan Stanley Initiates Coverage On Exelixis with Underweight Rating, Announces $19 Price Target",2018-09-10 07:28:00-04:00,EXEL,neutral
468679.0,Exelixis Announces New Recommendations For CABOMETYX Tablets In Updated Comprehensive Cancer Network Clinical Practice Guidelines,2018-09-07 08:02:00-04:00,EXEL,negative
468680.0,"Jim Cramer Weighs In On CarMax, AbbVie And More",2018-09-07 07:37:00-04:00,EXEL,neutral
468681.0,"Stocks Which Set New 52-Week Low Yesterday, August 21st",2018-08-22 09:11:00-04:00,EXEL,negative
468682.0,"Stocks Which Set New 52-Week Low Tues., Aug. 21, 2018",2018-08-21 14:56:00-04:00,EXEL,negative
468683.0,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",2018-08-21 08:40:00-04:00,EXEL,positive
468684.0,41 Biggest Movers From Yesterday,2018-08-21 04:47:00-04:00,EXEL,neutral
468685.0,28 Stocks Moving In Monday's Mid-Day Session,2018-08-20 12:35:00-04:00,EXEL,neutral
468686.0,Exelixis shares are down 6.8%; Not yet seeing any news to justify price action.,2018-08-20 10:06:00-04:00,EXEL,positive
468687.0,"Exelixis Q2 EPS $0.28 Beats $0.16 Estimate, Sales $186.11M Beat $157.37M Estimate",2018-08-01 17:23:00-04:00,EXEL,neutral
468688.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,EXEL,negative
468689.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,EXEL,neutral
468690.0,"BZ NOTE On Exelixis Spike Higher: Traders Likely Viewing Co.'s Renal Cancer Treatment Optimistically Following Comment on Bristol-Myers Q2 Earnings Conference Call It Will Receive Negative CHMP Opinion For OPDIVO, A Potential Renal Cancer Treatment",2018-07-26 10:47:00-04:00,EXEL,negative
468691.0,"Exelixis Shares Spike 2.8% Higher, Could Be Related To Chatter Of Negative CHMP Opinion For Renal Cell Carcinoma Treatment Discussed On Bristol-Myers Q2 Earnings Conference Call",2018-07-26 10:42:00-04:00,EXEL,negative
468692.0,"William Blair Views 4 Biotech/Pharma Stocks As 'Top Picks': Adamas Pharma, Aclaris Therapeutics, Biodelivery Sciences, Exelixis",2018-07-19 06:26:00-04:00,EXEL,positive
468693.0,Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine,2018-07-04 19:19:00-04:00,EXEL,neutral
468694.0,54 Biggest Movers From Yesterday,2018-06-27 04:51:00-04:00,EXEL,neutral
468695.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-06-26 12:32:00-04:00,EXEL,neutral
468696.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,EXEL,positive
468697.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-06-26 08:00:00-04:00,EXEL,neutral
468698.0,S&P Dow Jones Indices Announces 'Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400',2018-06-25 17:32:00-04:00,EXEL,positive
468699.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,EXEL,negative
468700.0,Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at #ASCO2018,2018-06-03 19:19:00-04:00,EXEL,positive
468701.0,UPDATE: Exelixis Says 10 New Trial Cohorts Added To Expansion Phase Of Combo Trial For Cabozantinib,2018-06-01 08:03:00-04:00,EXEL,neutral
468702.0,Exelixis Reports Further Expansion To Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combo With Anti-PD-L1 Immunotherapy In Patients With Locally-Advanced Or Metastatic Solid Tumors,2018-06-01 08:02:00-04:00,EXEL,positive
468703.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,EXEL,positive
468704.0,Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application For CABOMETYX (cabozantinib) In Previously Treated Advanced Hepatocellular Carcinoma,2018-05-29 16:08:00-04:00,EXEL,positive
468705.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,EXEL,neutral
468706.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,EXEL,neutral
468707.0,Exelixis' Partner Ipsen Announces EC Approval of CABOMETYX for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma; Triggers $50M Milestone Payment to Exelixis,2018-05-17 03:58:00-04:00,EXEL,positive
468708.0,55 Biggest Movers From Yesterday,2018-05-11 04:39:00-04:00,EXEL,neutral
468709.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-05-10 12:43:00-04:00,EXEL,neutral
468710.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,EXEL,neutral
468711.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-05-10 08:08:00-04:00,EXEL,neutral
468712.0,Exelixis Says IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer did Not Meet Primary Endpoint,2018-05-10 03:40:00-04:00,EXEL,negative
468713.0,"Jim Cramer Shares His Thoughts On Blackstone, Celgene And More",2018-05-04 07:52:00-04:00,EXEL,positive
468714.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,EXEL,negative
468715.0,"Exelixis Q1 EPS $0.37 Beats $0.13 Estimate, Sales $212.34M Beat $134.03M Estimate",2018-05-02 17:17:00-04:00,EXEL,neutral
468716.0,"Exelixis, Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer",2018-05-02 17:02:00-04:00,EXEL,negative
468717.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,EXEL,neutral
468718.0,Shares Of Exelixis Plunge After Report Its MODUL Trial Suspended Following A Review Of One Of Its Cohorts,2018-04-09 14:33:00-04:00,EXEL,negative
468719.0,"For Now, Traders Endorse Biotech Rally",2018-03-28 11:43:00-04:00,EXEL,positive
468720.0,Exelixis' Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX for Previously Treated Advanced Hepatocellular Carcinoma,2018-03-28 03:57:00-04:00,EXEL,positive
468721.0,Exelixis Partner Ipsen Earlier Received Positive Opinion On CABOMETYX For Renal Cell Carcinoma From Committee For Medicinal Products For Human Use; Opinion Will Be Reviewed By European Commission For Approval,2018-03-23 07:59:00-04:00,EXEL,positive
468722.0,Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX,2018-03-15 08:02:00-04:00,EXEL,neutral
468723.0,Exelixis Earlier Announced Partner Daiichi Sankyo's Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan,2018-02-27 09:31:00-05:00,EXEL,neutral
468724.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2018",2018-02-27 09:22:00-05:00,EXEL,positive
468725.0,Oppenheimer Upgrades Exelixis to Outperform,2018-02-27 08:12:00-05:00,EXEL,neutral
468726.0,"Exelixis Reports Q4 EPS $0.12, Inline, Sales $120.1M vs $120.3M Est.",2018-02-26 16:41:00-05:00,EXEL,neutral
468727.0,Exelixis Q4 Earnings Outlook,2018-02-26 11:14:00-05:00,EXEL,neutral
468728.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,EXEL,neutral
468729.0,"Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib, Showed 54% Objective Response Rate And 43% Stable Disease Rate Among 35 Evaluable Patients",2018-02-13 16:48:00-05:00,EXEL,positive
468730.0,Exelixis Gives an Update on its Phase 1 Trial for Cabozantinib in Combination with Nivolumab,2018-02-07 08:06:00-05:00,EXEL,neutral
468731.0,Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium,2018-01-21 10:20:00-05:00,EXEL,negative
468732.0,STAT News' Adam Feuerstein Tweets '$EXEL data look basically in line with expectations.',2018-01-16 17:40:00-05:00,EXEL,neutral
468733.0,"Exelixis Shares Resume, Up ~1.9% After Hours",2018-01-16 17:32:00-05:00,EXEL,positive
468734.0,Exelixis Shares To Resume Trade At 5:30 p.m. EST,2018-01-16 17:25:00-05:00,EXEL,positive
468735.0,"Exelixis and Ipsen Announce Phase 3 Trial Shows Cabozantinib Met Primary Endpoint, To Submit NDA In Q1 18",2018-01-16 17:02:00-05:00,EXEL,neutral
468736.0,Exelixis Shares Halted News Pending,2018-01-16 16:55:00-05:00,EXEL,positive
468737.0,Diplomat Pharmacy Dispensing Exelixis CABOMETYX Now with Expanded Indication,2018-01-15 16:43:00-05:00,EXEL,neutral
468738.0,"Exelixis Enters Exclusive Licensing Agreement With StemSynergy For CK1a Activator Program, Will Pay StemSynergy $3M Upfront And Up To $3.5M In R&D Funding, In Addition To Variety Of Milestone Payments",2018-01-08 11:36:00-05:00,EXEL,positive
468739.0,"Exelixis Says 4 New Trial Cohorts, Including NSCLC, CRPC, Added To Expansion Phase Of Combo Trial For Cabozantinib with Atezolizumab",2018-01-04 08:17:00-05:00,EXEL,neutral
468740.0,28 Stocks Moving In Wednesday's Pre-Market Session,2017-12-20 08:12:00-05:00,EXEL,neutral
468741.0,UPDATE: Exelixis Says Co. Is 'prepared to fully support expanded indication immediately',2017-12-19 14:55:00-05:00,EXEL,positive
468742.0,"UPDATE: Exelixis Highlights PDUFA Date For CABOMETYX Feb. 15, 2018",2017-12-19 14:55:00-05:00,EXEL,neutral
468743.0,Exelixis Reports FDA Approval Of CABOMETYX Tablets For Previously Untreated Advanced Renal Cell Carinoma,2017-12-19 14:55:00-05:00,EXEL,positive
468744.0,"Stifel 2017 Healthcare Conference Begins Today, Presenters Include: Seres Therapeutics, Verastem, TherapeuticsMD, Aerie Pharmaceuticals, Mednax, Celgene, TransEnterix, Exelixis, Tandem Diabetes Care and Masimo",2017-11-14 09:36:00-05:00,EXEL,positive
468745.0,52 Stocks Moving In Thursday's Mid-Day Session,2017-11-02 12:29:00-04:00,EXEL,neutral
468746.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-11-02 08:25:00-04:00,EXEL,neutral
468747.0,"Exelixis Reports Q3 Adj. EPS $0.26 vs $(0.04) In Same Qtr. Last Year, Sales $152.5M vs $62.2M YoY",2017-11-01 17:35:00-04:00,EXEL,neutral
468748.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,EXEL,neutral
468749.0,Benzinga's Option Alert Recap From October 16,2017-10-16 16:34:00-04:00,EXEL,positive
468750.0,Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge,2017-10-16 14:30:00-04:00,EXEL,neutral
468751.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,EXEL,neutral
468752.0,Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline,2017-10-16 12:11:00-04:00,EXEL,positive
468753.0,Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views,2017-10-16 10:10:00-04:00,EXEL,positive
468754.0,Exelixis Option Alert: Feb 16 $28 Puts Sweep (16) at the Ask: 500 @ $3.0 vs 57 OI; Ref=$30.07,2017-10-16 09:41:00-04:00,EXEL,positive
468755.0,Here's Why Exelixis Is Trading Higher By 20%,2017-10-16 09:16:00-04:00,EXEL,neutral
468756.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-16 08:17:00-04:00,EXEL,neutral
468757.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher; Netflix Earnings In Focus,2017-10-16 07:36:00-04:00,EXEL,neutral
468758.0,Exelixis Granted Priority Review for CABOMETYX by the FDA,2017-10-16 06:59:00-04:00,EXEL,positive
468759.0,"Exelixis' Phase 3 CELESTIAL Trial Met its Primary Endpoint, Company to Submit a Supplemental NDA in Q1 2018",2017-10-16 06:59:00-04:00,EXEL,neutral
468760.0,Exelixis to Receive $10M Milestone Payment from Bristol-Myers for Submission of Clinical Trial Authorization for ROR?t Inverse Agonist Program,2017-10-04 08:02:00-04:00,EXEL,neutral
468761.0,"Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma",2017-09-25 09:30:00-04:00,EXEL,neutral
468762.0,Exelixis Shares Sell Off ~12% Fri. As $28 Resistance Level Holds; Stock Had Been Range Bound Between $26-$28 Over Most Of Jul.-Sept.,2017-09-22 13:30:00-04:00,EXEL,positive
468763.0,The Street Has Finally Recognized The Exelixis Clinical Program Potential,2017-09-22 13:13:00-04:00,EXEL,neutral
468764.0,12 Biggest Mid-Day Losers For Friday,2017-09-22 12:34:00-04:00,EXEL,negative
468765.0,Leerink Swann Downgrades Exelixis to Market Perform,2017-09-22 08:07:00-04:00,EXEL,neutral
468766.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,EXEL,neutral
468767.0,RBC Initiates Coverage on 6 Pharma Stocks After Hours,2017-09-14 16:47:00-04:00,EXEL,neutral
468768.0,Watch These 5 Huge Call Purchases In Monday Trade,2017-09-11 04:22:00-04:00,EXEL,positive
468769.0,"Ipsen, Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib vs Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017",2017-09-10 17:48:00-04:00,EXEL,positive
468770.0,Benzinga's Option Alert Recap From September 8,2017-09-08 16:21:00-04:00,EXEL,positive
468771.0,Exelixis Option Alert: Nov 17 $29 Calls at the Bid: 500 @ $1.45 vs 163 OI; Ref=$25.7,2017-09-08 09:35:00-04:00,EXEL,positive
468772.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,EXEL,neutral
468773.0,18 Biggest Mid-Day Losers For Thursday,2017-09-07 12:53:00-04:00,EXEL,negative
468774.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-08-16 08:11:00-04:00,EXEL,neutral
468775.0,A Peek Into The Markets: U.S. Stock Futures Rise; All Eyes On Fed Minutes,2017-08-16 07:14:00-04:00,EXEL,neutral
468776.0,Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX,2017-08-16 07:03:00-04:00,EXEL,neutral
468777.0,The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom,2017-08-03 14:41:00-04:00,EXEL,negative
468778.0,Deutsche Bank Downgrades Exelixis to Hold,2017-08-03 07:15:00-04:00,EXEL,neutral
468779.0,Exelixies Reaffirms FY17 Guidance,2017-08-02 17:32:00-04:00,EXEL,neutral
468780.0,Exelixis W/ Bristol-Myers Squibb Announces Start Of Phase 3 Trial For Cabozantinib in Combinations,2017-08-02 17:31:00-04:00,EXEL,neutral
468781.0,"Exelixis Reports Q2 EPS $0.06 vs $0.04 Est., Sales $99M vs $85.31M Est.",2017-08-02 17:28:00-04:00,EXEL,neutral
468782.0,Exelixis Reports Settlement Of Dispute With Genentech Related To Cos.' Collaboration Deal For Cobimetinib,2017-07-20 07:12:00-04:00,EXEL,negative
468783.0,Exelixis Shares Up ~2% Over Last Few Mins As Traders Circulating Chatter Co. Could Be Interested In Considering Sale,2017-06-29 15:44:00-04:00,EXEL,positive
468785.0,Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide,2017-06-21 12:02:00-04:00,EXEL,positive
468787.0,Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations,2017-06-21 10:11:00-04:00,EXEL,positive
468789.0,15 Biggest Mid-Day Gainers For Monday,2017-06-19 12:24:00-04:00,EXEL,neutral
468790.0,15 Stocks Moving In Monday's Pre-Market Session,2017-06-19 08:37:00-04:00,EXEL,neutral
468791.0,"Exelixis Announces IRC Confirms Cabozantinib Significantly Improved Progression-Free Survival Compared to Sunitinib, U.S. Regulatory Submission Remains on Track for Q3 2017",2017-06-19 08:06:00-04:00,EXEL,positive
468793.0,Exelixis Reports Initiation Of Phase 1b Trial Of Cabozantinib In Combo With Atezolizumab In Patients With Locally-Advanced Metastatic Solid Tumors,2017-06-12 08:10:00-04:00,EXEL,positive
468794.0,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 13:48:00-04:00,EXEL,neutral
468795.0,Watch These 8 Huge Call Purchases In Wednesday Trade,2017-05-31 04:15:00-04:00,EXEL,positive
468796.0,Option Alert: Exelixis Jul 14.0 Calls Sweep: 503 @  ASK  $5.10: 1788 traded vs 0 OI:  Earnings 8/3 After Close (est)  $18.80 Ref,2017-05-30 11:36:00-04:00,EXEL,positive
468797.0,Watch These 5 Huge Put Purchases In Wednesday Trade,2017-05-24 04:52:00-04:00,EXEL,positive
468798.0,Benzinga's Option Alert Recap From May 23,2017-05-23 16:36:00-04:00,EXEL,positive
468800.0,Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss,2017-05-19 14:30:00-04:00,EXEL,negative
468801.0,Stifel's ASCO Abstract Cheat Sheet,2017-05-18 09:57:00-04:00,EXEL,negative
468802.0,"Deutsche Bank Healthcare Conference Begins Today; Presenters Include Synergy Pharma, Exelixis, AbbVie, Collegium Pharma, Zimmer Biomet, Luminex, CRISPR Therapeutics, & Edwards Lifesciences",2017-05-03 08:22:00-04:00,EXEL,neutral
468803.0,18 Biggest Mid-Day Gainers For Tuesday,2017-05-02 12:28:00-04:00,EXEL,neutral
468804.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-02 08:05:00-04:00,EXEL,neutral
468805.0,"Exelixis Q1 EPS $0.05 vs $(0.01) Est, Sales $80.89M vs $65.23M Est",2017-05-01 16:20:00-04:00,EXEL,neutral
468806.0,Volume Spike in Exelixis,2017-04-03 11:19:00-04:00,EXEL,neutral
468807.0,"Exelixis Shares Up 2%; Needham Earlier Initiated with a Buy Rating, $28 Price Target",2017-03-31 10:20:00-04:00,EXEL,positive
468808.0,Exelixis Shares Down Premarket Following Last Night's After-Hours Announcement Of $80.1M Debt Repayment,2017-03-30 09:28:00-04:00,EXEL,negative
468809.0,"Benzinga's Top Upgrades, Downgrades For March 16, 2017",2017-03-16 09:30:00-04:00,EXEL,positive
468810.0,Oppenheimer Initiates Coverage On Exelixis With Perform,2017-03-16 09:21:00-04:00,EXEL,neutral
468811.0,Exelixis Turn Negative Following Circulation Of Journal Of Clinical Oncology Cautious Report On Cabozantinib Earlier,2017-03-08 14:22:00-05:00,EXEL,negative
468812.0,Traders Circulating Cautious Article From Journal Of Clinical Oncology Highlighting Exelis Drug Cabozantinib,2017-03-08 13:00:00-05:00,EXEL,negative
468813.0,Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma,2017-03-06 09:05:00-05:00,EXEL,positive
468814.0,Exelixis' Cabozantinib Granted FDA Orphan Drug Designation,2017-03-05 17:54:00-05:00,EXEL,positive
468815.0,Icahn's (Potential) Move Into Biotech,2017-03-04 19:25:00-05:00,EXEL,neutral
468816.0,20 Biggest Mid-Day Losers For Tuesday,2017-02-28 13:04:00-05:00,EXEL,negative
468817.0,"Benzinga's Top Upgrades, Downgrades For February 28, 2017",2017-02-28 09:30:00-05:00,EXEL,positive
468818.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-02-28 08:30:00-05:00,EXEL,neutral
468819.0,"Stifel Nicolaus Downgrades Exelixis To Hold, Raises Price Target to $22",2017-02-28 06:30:00-05:00,EXEL,neutral
468820.0,"Exelixis Reports Q4 EPS $0.12 vs. $(0.01) Est., Sales $77.58M vs. $66.5M Est.",2017-02-27 16:17:00-05:00,EXEL,neutral
468821.0,Exelixis Reprots Clinical Trial Partnership with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors,2017-02-27 07:08:00-05:00,EXEL,positive
468822.0,venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter,2017-02-22 08:32:00-05:00,EXEL,positive
468823.0,"venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders",2017-02-10 16:16:00-05:00,EXEL,neutral
468824.0,Benzinga's Option Alert Recap From February 6,2017-02-06 16:52:00-05:00,EXEL,positive
468825.0,Option Alert: Exelixis Feb 20.0 Calls Sweep: 508 @  ASK  $1.60: 1448 traded vs 5233 OI:  Earnings 2/27 After Close  $20.13 Ref,2017-02-06 11:37:00-05:00,EXEL,positive
468826.0,Adam Feuerstein Tweets: $EXEL down on Takeda cabo licensing deal because Takeda didn't buy the company.,2017-01-31 12:44:00-05:00,EXEL,neutral
468827.0,"UPDATE: Exelixis Received $50M Upfront Payment, is Eligible for Future Regulatory, Commercial Milestones of $95M",2017-01-30 18:01:00-05:00,EXEL,neutral
468828.0,"Exelixis Reports Exclusive Licensing Deal with Takeda for Commercialization, Development of Cabozantinib in Japan",2017-01-30 18:00:00-05:00,EXEL,positive
468829.0,Benzinga's Option Alert Recap From January 30,2017-01-30 17:15:00-05:00,EXEL,positive
468830.0,Option Alert: Exelixis Jan18 50.0 Calls: 500 @  ASK  $2.75: 569 traded vs 891 OI:  Earnings 2/23 After Close (est)  $29.44 Ref,2017-01-30 10:54:00-05:00,EXEL,positive
468831.0,Watch These 10 Huge Call Purchases In Wednesday Trade,2017-01-25 04:05:00-05:00,EXEL,positive
468832.0,Benzinga's Option Alert Recap From January 24,2017-01-24 17:26:00-05:00,EXEL,positive
468833.0,Option Alert: Exelixis Mar 22.0 Calls Sweep: 1500 @  ASK  $0.90: 1510 traded vs 19 OI:  Earnings 2/28 After Close (est)  $18.04 Ref,2017-01-24 11:19:00-05:00,EXEL,positive
468834.0,Watch These 8 Huge Call Purchases In Monday Trade,2017-01-23 04:03:00-05:00,EXEL,positive
468835.0,Option Alert: Exelixis Feb 20.0 Calls Sweep: 500 @  ASK  $0.90: 500 traded vs 2179 OI:  Earnings 2/28 After Close (est)  $17.79 Ref,2017-01-20 10:17:00-05:00,EXEL,positive
468836.0,Watch These 7 Huge Put Purchases In Tuesday Trade,2017-01-17 06:20:00-05:00,EXEL,positive
468837.0,Option Alert: Exelixis Feb 18.0 Puts Sweep: 653 @  ASK  $1.55: 3560 traded vs 11k OI:  Earnings 2/28 After Close (est)  $19.18 Ref,2017-01-13 10:35:00-05:00,EXEL,positive
468838.0,Option Alert: Exelixis Feb 21.0 Calls Sweep: 667 @  ASK  $1.099: 699 traded vs 246 OI:  Earnings 2/28 After Close (est)  $18.87 Ref,2017-01-12 14:51:00-05:00,EXEL,positive
468839.0,Exelixis Announces Genentech has Withdrawn Counterclaim Against Exelixis in Ongoing Jams Arbitration,2017-01-09 05:17:00-05:00,EXEL,neutral
468840.0,Option Alert: Exelixis Jan $17 Call; 2869 @Bid @$0.40; Ref = $14.60,2017-01-03 10:56:00-05:00,EXEL,positive
468841.0,6 Best Biotech Stocks Of 2016,2016-12-23 11:25:00-05:00,EXEL,positive
468842.0,Exelixis Shares Edge Lower as Traders Circulating Journal of Clinical Oncology Article 'Future Challenges for Drug Development in Renal Cell Carcinoma',2016-12-22 14:58:00-05:00,EXEL,positive
468843.0,"Exelixis, Ipsen Licensing Agreement for Commercialization and Development of Cabozantinib to Now Include Canada",2016-12-21 03:59:00-05:00,EXEL,positive
468844.0,Watch These 7 Huge Put Purchases In Monday Trade,2016-12-19 04:25:00-05:00,EXEL,positive
468845.0,Watch These 5 Huge Put Purchases In Thursday Trade,2016-12-15 04:25:00-05:00,EXEL,positive
468846.0,Option Alert: EXEL Jan17 16.0 Puts Sweep: 2644 @  ASK  $1.35: 2654 traded vs 265 OI:  Earnings 2/28 After Close (est)  $16.29 Ref,2016-12-14 10:27:00-05:00,EXEL,positive
468847.0,Mid-Afternoon Market Update: Dow Surges 250 Points; Oxford Industries Shares Tumble,2016-12-07 14:53:00-05:00,EXEL,positive
468848.0,Mid-Day Market Update: Dave & Buster's Climbs On Upbeat Results; Sigma Designs Shares Slide,2016-12-07 12:16:00-05:00,EXEL,positive
468849.0,18 Stocks Moving In Tuesday's Pre-Market Session,2016-12-06 08:25:00-05:00,EXEL,neutral
468850.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,EXEL,positive
468851.0,Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at Society for Melanoma Research 2016 Congress That Support Genentech's Planned Phase 3 Pivotal Trials,2016-11-07 04:12:00-05:00,EXEL,positive
468852.0,25 Biggest Mid-Day Gainers For Friday,2016-11-04 12:43:00-04:00,EXEL,neutral
468853.0,22 Stocks Moving In Friday's Pre-Market Session,2016-11-04 08:36:00-04:00,EXEL,neutral
468854.0,"Exelixis Reports Q3 Loss/Share $0.04 vs $0.13 Est, Rev $42.7M vs $42.86M Est",2016-11-03 17:38:00-04:00,EXEL,neutral
468855.0,"Deutsche Bank Initiates Coverage On Exelixis, Inc. - Common Stock at Buy",2016-11-03 06:05:00-04:00,EXEL,neutral
468856.0,"Hearing Money Map Press Recommends Exelixis, Inc. As New Buy",2016-10-17 11:16:00-04:00,EXEL,positive
468857.0,Option Alert: EXEL Oct $12 Call; 2707 @Bid @$0.97; Ref = $12.70,2016-10-11 11:15:00-04:00,EXEL,positive
468858.0,"Exelixis Shares Turn Lower Over Last Few Mins, Down ~2% for Session; $13 May Have Been a Notable Support Level",2016-10-10 12:00:00-04:00,EXEL,positive
468859.0,16 Stocks Moving In Monday's Pre-Market Session,2016-10-10 08:42:00-04:00,EXEL,neutral
468860.0,Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016,2016-10-10 04:08:00-04:00,EXEL,positive
468861.0,18 Biggest Mid-Day Losers For Friday,2016-10-07 13:16:00-04:00,EXEL,negative
468862.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-07 08:29:00-04:00,EXEL,neutral
468863.0,Exelixis Presents Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors at ESMO 2016,2016-10-07 04:55:00-04:00,EXEL,positive
468864.0,"Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016",2016-10-07 04:54:00-04:00,EXEL,neutral
468865.0,Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher,2016-09-29 14:38:00-04:00,EXEL,positive
468866.0,Mid-Day Market Update:  Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide,2016-09-29 12:25:00-04:00,EXEL,negative
468867.0,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 10:06:00-04:00,EXEL,negative
468868.0,Technical Alert: Exelixis Sharply Lower,2016-09-28 14:39:00-04:00,EXEL,neutral
468869.0,"Leerink Out Defending Exelixis, Says Selloff Overdone",2016-09-28 13:17:00-04:00,EXEL,neutral
468870.0,12 Biggest Mid-Day Losers For Wednesday,2016-09-28 13:15:00-04:00,EXEL,negative
468871.0,"Exelixis Shares Trading Down 13.5%, Traders Attributing Weakness In Shares To Cabometyx, Opdivo Data Compared To Other Combinations",2016-09-28 12:05:00-04:00,EXEL,positive
468872.0,Exelixis Sells off to Low of $12.61 on Volume,2016-09-28 11:46:00-04:00,EXEL,negative
468873.0,12 Biggest Mid-Day Gainers For Monday,2016-09-26 12:10:00-04:00,EXEL,neutral
468874.0,Stocks Hitting 52-Week Highs,2016-09-26 10:20:00-04:00,EXEL,neutral
468875.0,15 Stocks Moving In Monday's Pre-Market Session,2016-09-26 08:30:00-04:00,EXEL,neutral
468876.0,Exelis Gets $15M Milestone Payment for Initiation of Phase 3 Study,2016-09-26 06:02:00-04:00,EXEL,neutral
468877.0,"Option Alert: EXEL Fri $14 Calls at the bid: Volume of 5,000 @ 1.351 vs 786 Open Interest",2016-09-21 11:01:00-04:00,EXEL,positive
468878.0,Stocks Hitting 52-Week Highs,2016-09-21 10:21:00-04:00,EXEL,neutral
468879.0,"Exelixis Shares Indicated Up ~4% Premarket Amid Recent Pharma M&A, Following Co. Report Tues. Afternoon an Update on CABOzantinib Will Be Presented at ESMO '16 Congress on Oct. 10, '16",2016-09-21 08:25:00-04:00,EXEL,positive
468880.0,12 Biggest Mid-Day Gainers For Wednesday,2016-09-14 12:51:00-04:00,EXEL,neutral
468881.0,Option Alert: Exelixis Jan 20 $15 Puts at the bid: 2000 @ 3.0 vs. Open Interest 0,2016-09-14 10:46:00-04:00,EXEL,positive
468882.0,Stocks Hitting 52-Week Highs,2016-09-14 10:10:00-04:00,EXEL,neutral
468883.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-09-14 08:32:00-04:00,EXEL,neutral
468884.0,Exelixis Announces EC Approves CABOMETYX Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy,2016-09-14 04:13:00-04:00,EXEL,positive
468885.0,Option Alert: EXEL Jan $15 Put @Bid @$4.80; Ref=$12.44,2016-09-13 10:39:00-04:00,EXEL,positive
468886.0,Exelixis Announces Phase 3 Trial Of CELESTIAL Interim Analysis Results; It Is Determined The Study Should Continue Without Modifications,2016-09-06 17:12:00-04:00,EXEL,positive
468887.0,Exelixis Pops to High of $12.05 on Volume,2016-09-06 10:54:00-04:00,EXEL,neutral
468888.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-09-06 08:22:00-04:00,EXEL,neutral
468889.0,Watch These 7 Huge Put Purchases In Friday Trade,2016-08-05 03:16:00-04:00,EXEL,positive
468890.0,Major Averages Close Thursday's Session Mostly Unchanged,2016-08-04 16:52:00-04:00,EXEL,neutral
468891.0,20 Biggest Mid-Day Gainers For Thursday,2016-08-04 12:49:00-04:00,EXEL,neutral
468892.0,Option Alert: EXEL Jan17 11.0 Puts Sweep: 4497 @  ASK  $1.45: 4594 traded vs 0 OI: $11.42 Ref,2016-08-04 11:49:00-04:00,EXEL,positive
468893.0,Stocks Hitting 52-Week Highs,2016-08-04 10:25:00-04:00,EXEL,neutral
468894.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-04 08:35:00-04:00,EXEL,neutral
468895.0,"After-Hours Gainers Aug. 3, '16: OCUL Up 22%, SQ 14.9%, CBMX 13.5%, AXGN 10%, AVID 8.7%, PODD 8.6%, NSTG 8.3%, JACK 8%, EXEL 7.7%",2016-08-03 19:10:00-04:00,EXEL,positive
468896.0,"Exelixis Reports Q2 EPS $(0.16) vs. Est. $(0.27), Rev. $36.3M vs. Est. $17.9M",2016-08-03 18:00:00-04:00,EXEL,neutral
468897.0,Option Alert:  SWEEP (SELL) - EXEL Jan $8 Call - 1083 @ 1.0 in 20 orders. 1083 traded. OI: 827,2016-06-30 15:07:00-04:00,EXEL,positive
468898.0,Option Alert: EXEL Aug16 8.0 Calls: 500 @  ASK  $0.55: 1010 traded vs 3117 OI:  Earnings 8/9  $7.71 Ref,2016-06-22 10:25:00-04:00,EXEL,positive
468899.0,9 Biggest Mid-Day Gainers For Monday,2016-06-06 12:17:00-04:00,EXEL,neutral
468900.0,Stocks Hitting 52-Week Highs,2016-06-06 10:22:00-04:00,EXEL,neutral
468901.0,10 Stocks Moving In Monday's Pre-Market Session,2016-06-06 08:30:00-04:00,EXEL,neutral
468902.0,Pre Market Movers,2016-06-06 08:00:00-04:00,EXEL,neutral
468903.0,"Exelixis, Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting",2016-06-06 07:30:00-04:00,EXEL,positive
468904.0,"Exelixis, Ipsen Announce Phase 3 Trial Results of CABOMETYX Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at #ASCO16",2016-06-05 09:00:00-04:00,EXEL,positive
468905.0,Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for Combination of Cobimetinib and Atezolizumab at #ASCO16,2016-06-05 08:55:00-04:00,EXEL,neutral
468906.0,Option Alert: EXEL Jan18 7.0 Calls: 1397 @  ASK  $1.50: 1403 traded vs 3833 OI: $6.58 Ref,2016-05-31 12:23:00-04:00,EXEL,positive
468907.0,Exelixis Offers Results from Randomized Phase 2 Trial of CABOSUN Showed Significant Improvement in Progression-Free Survival vs. Sunitinib,2016-05-23 09:04:00-04:00,EXEL,positive
468908.0,Mid-Afternoon Market Update: Dow Tumbles 1%; Nordstrom Shares Down Following Earnings Miss,2016-05-13 14:33:00-04:00,EXEL,positive
468909.0,"Director Willsey Buys 60,000 Shares of Exelixis @$4.97/Share -Form 4",2016-05-11 17:28:00-04:00,EXEL,positive
468910.0,1Globe Capital  Reports 6.14% Passive Stake in Exelixis in 13G,2016-04-28 11:45:00-04:00,EXEL,positive
468911.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-04-26 08:29:00-04:00,EXEL,neutral
468912.0,Exelixis Gets FDA Approval For Its CABOMETYX Tablets,2016-04-25 14:52:00-04:00,EXEL,positive
468913.0,Mid-Afternoon Market Update: Crude Oil Down 2%; KKR Shares Slide Following Q1 Results,2016-04-25 14:31:00-04:00,EXEL,negative
468914.0,Exelixis Confirms FDA Approval of CABOMETYX Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy,2016-04-25 13:53:00-04:00,EXEL,positive
468915.0,Exelixis PR Confirms FDA Approval of CABOMETYX Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy,2016-04-25 13:53:00-04:00,EXEL,positive
468916.0,Exelis CABOMETYX Gets FDA Approval For Renal Label,2016-04-25 13:25:00-04:00,EXEL,positive
468917.0,Option Alert: EXEL Aug16 7.0 Calls Sweep: 1575 @  ASK  $0.15: 1590 traded vs 5140 OI:  Earnings 5/5  $4.28 Ref,2016-04-04 13:03:00-04:00,EXEL,positive
468918.0,Exelixis Shares Up 5-6% Following Earlier Stifel Upgrade To Buy,2016-04-04 11:04:00-04:00,EXEL,positive
468919.0,Option Alert: EXEL May16 3.5 Calls: 952 @  Above Ask!  $0.70: 2000 traded vs 15 OI:  Earnings 5/5  $3.84 Ref,2016-03-28 14:25:00-04:00,EXEL,positive
468920.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-03-01 08:24:00-05:00,EXEL,neutral
468921.0,7 Stocks Moving In Today's After-Hours Session,2016-02-29 18:01:00-05:00,EXEL,neutral
468922.0,"Exelixis Inks Licensing Deal With Ipsen,  ~$855 Million",2016-02-29 17:14:00-05:00,EXEL,neutral
468923.0,Exelixis Sees FY16 OpEx $240M-$270M,2016-02-29 16:10:00-05:00,EXEL,neutral
468924.0,"Exelixis Reports Q4 EPS $(0.19) vs $(0.22) Est., Sales $9.9M vs $8.2M Est.",2016-02-29 16:09:00-05:00,EXEL,neutral
468925.0,"Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan",2016-02-29 16:03:00-05:00,EXEL,positive
468926.0,Exelixis Reports EMA Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma,2016-01-28 16:14:00-05:00,EXEL,positive
468927.0,"Exelixis Reports FDA Has Deemed NDA Sufficiently Complete, Has Granted Priority Review for Cabozantinib for Treatment of Advance Renal Cell Carcinoma",2016-01-28 08:05:00-05:00,EXEL,positive
468928.0,Earlier Leerink Swann Upgraded Exelixis to Outperform,2016-01-19 11:04:00-05:00,EXEL,neutral
468929.0,Exelixis Gives Marketing Authorization Application For Cabozantinib in EU For Advanced Renal Cell Carcinoma,2016-01-11 08:34:00-05:00,EXEL,positive
468930.0,Exelixis Spikes Following Phase 3 Results Of Cabozantinib; EU Filing Planned For Early 2016,2016-01-05 09:09:00-05:00,EXEL,neutral
468931.0,Benzinga's Top #PreMarket Gainers,2016-01-05 08:13:00-05:00,EXEL,positive
468932.0,5 Stocks You Should Be Watching Today,2016-01-05 04:30:00-05:00,EXEL,neutral
468933.0,Exelixis +11.52% After-Hours @$6.14 Following Announcement of Positive Phase 3 Cabozantinib Trial Results,2016-01-04 17:39:00-05:00,EXEL,positive
468934.0,UPDATE: Exelixis Says EU Filing for Cabozantinib Planned for Early '16,2016-01-04 17:09:00-05:00,EXEL,neutral
468935.0,Exelixis Reports Results from Subgroup Analyses of METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma: Data Further Underscores Clinical Benefit,2016-01-04 17:08:00-05:00,EXEL,positive
468936.0,Exelixis Completes Submission of New Drug Application for Cabozantinib for Advanced Renal Carcinoma Treatment,2015-12-23 08:30:00-05:00,EXEL,positive
468937.0,Exelixis Announces European Commission Approval of COTELLIC for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma,2015-11-25 09:34:00-05:00,EXEL,positive
468938.0,Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress,2015-11-21 20:54:00-05:00,EXEL,positive
468939.0,"Exelixis Reports Q3 EPS $(0.22) vs. Est. $(0.20), Rev. $9.854M vs. Est. $9.08M",2015-11-10 16:28:00-05:00,EXEL,neutral
468940.0,"Release from Daiichi Sankyo, Plexxikon Shows Co.'s to Co-Promote Cobimetinib in Combo with Zelboraf with Genentech, Exelixis",2015-11-10 16:15:00-05:00,EXEL,neutral
468941.0,Exelixis to Resume Trading @2:00 PM ET,2015-11-10 13:43:00-05:00,EXEL,neutral
468942.0,Exelixis Release Confirms FDA Approval of COTELLIC in Combo with Vemurafenib for Treatment of Advanced Melanoma,2015-11-10 13:38:00-05:00,EXEL,positive
468943.0,Roche's Genentech Confirms FDA Approval of Cotellic in Combo with Zelboraf in Advanced Melanoma,2015-11-10 13:04:00-05:00,EXEL,positive
468944.0,"FDA Earlier Reported Approval of Roche, Exelixis' Cotellic for Combo Skin Cancer Therapy",2015-11-10 12:04:00-05:00,EXEL,negative
468945.0,Shares of Exelixis Halted News Pending,2015-11-10 11:08:00-05:00,EXEL,positive
468946.0,FDA Approves Cotellic as Part of Combination Treatment for Advanced Melanoma,2015-11-10 10:57:00-05:00,EXEL,positive
468947.0,Exelixis Begins Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer,2015-10-22 08:09:00-04:00,EXEL,negative
468948.0,Morning Market Gainers,2015-10-06 09:43:00-04:00,EXEL,neutral
468949.0,Benzinga's Top #PreMarket Gainers,2015-10-06 08:16:00-04:00,EXEL,positive
468950.0,Exelixis Announces Positive Overall Survival Results from coBRIM Phase 3 Pivotal Trial,2015-10-06 04:23:00-04:00,EXEL,positive
468951.0,Morning Market Losers,2015-09-28 09:59:00-04:00,EXEL,negative
468952.0,Benzinga's Top #PreMarket Losers,2015-09-28 08:25:00-04:00,EXEL,negative
468953.0,Exelixis Resumes Trading +18% Following Announcement of Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma,2015-09-25 18:41:00-04:00,EXEL,positive
468954.0,European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma,2015-09-25 07:43:00-04:00,EXEL,positive
468955.0,Cramer's Stock To Buy After A Fed Rate Hike,2015-09-16 17:00:00-04:00,EXEL,neutral
468956.0,"Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, Marathon Oil, Exelixis",2015-09-16 06:34:00-04:00,EXEL,positive
468957.0,William Blair's Best Ideas In A Volatile Market,2015-08-27 14:36:00-04:00,EXEL,positive
468958.0,Morning Market Gainers,2015-08-27 09:43:00-04:00,EXEL,neutral
468959.0,Benzinga's Top #PreMarket Gainers,2015-08-27 08:12:00-04:00,EXEL,positive
468960.0,Exelixis +10% Premarket Following Announcement of Regulatory Approval of Cobimetinib in Switzerland,2015-08-27 07:31:00-04:00,EXEL,positive
468961.0,Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland,2015-08-27 06:01:00-04:00,EXEL,positive
468962.0,Benzinga's Top #PreMarket Gainers,2015-08-25 08:14:00-04:00,EXEL,positive
468963.0,FDA Grants Breakthrough Therapy Designation to Exelixis' Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy,2015-08-24 08:30:00-04:00,EXEL,positive
468965.0,"Exelixis Reports Q2 Loss of $0.22/Share vs Loss of $0.21/Share Est., Sales $8M vs $8.7M Est.",2015-08-11 16:13:00-04:00,EXEL,negative
468966.0,Exelixis Prices 25M Share Offering @$5.40/Share,2015-07-23 20:50:00-04:00,EXEL,positive
468967.0,Morning Market Losers,2015-07-21 09:55:00-04:00,EXEL,negative
468968.0,Benzinga's Top #PreMarket Losers,2015-07-21 08:16:00-04:00,EXEL,negative
468969.0,Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold Dwindles,2015-07-20 12:03:00-04:00,EXEL,neutral
468970.0,Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views,2015-07-20 10:18:00-04:00,EXEL,neutral
468971.0,Morning Market Gainers,2015-07-20 09:39:00-04:00,EXEL,neutral
468972.0,Exelixis Up 50% After Meteroric METEOR Results,2015-07-20 09:38:00-04:00,EXEL,neutral
468973.0,Benzinga's Top #PreMarket Gainers,2015-07-20 08:08:00-04:00,EXEL,positive
468974.0,"Exelixis Announces Positive Top-Line Results from METEOR, Phase 3 Pivotal Trial of Cabozantinib Vs. Everolimus in Patients with Metastatic Renal Cell Carcinoma",2015-07-20 07:03:00-04:00,EXEL,positive
468975.0,"Exelixis Shares Halted, Says Study Met Primary Endpoint",2015-07-20 07:02:00-04:00,EXEL,positive
468976.0,"Exelixis Names Chris Senner as Executive VP, CFO",2015-07-15 20:22:00-04:00,EXEL,neutral
468977.0,Filing from Exelixis Shows Registration for Common Stock Offering,2015-07-15 17:06:00-04:00,EXEL,neutral
468978.0,Hearing Positive Comments from Agora Financial in Exelixis,2015-07-14 14:17:00-04:00,EXEL,positive
468979.0,Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,2015-07-13 08:30:00-04:00,EXEL,neutral
468980.0,"Exelixis Gives Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound",2015-07-01 08:45:00-04:00,EXEL,neutral
468981.0,Benzinga's Top #PreMarket Losers,2015-06-29 08:18:00-04:00,EXEL,negative
468983.0,Watch These 10 Stocks Over The Weekend,2015-06-20 11:31:00-04:00,EXEL,neutral
468984.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,EXEL,neutral
468985.0,Morning Market Gainers,2015-06-01 10:16:00-04:00,EXEL,neutral
468986.0,Benzinga's Top #PreMarket Gainers,2015-06-01 08:08:00-04:00,EXEL,positive
468987.0,Exelixis Shares Rise 19% Premarket Following Announcement of Positive Phase 2 Cabozantinib Results at ASCO,2015-06-01 06:24:00-04:00,EXEL,positive
468988.0,Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged NSCLC at ASCO,2015-05-31 09:43:00-04:00,EXEL,positive
468989.0,Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type NSCLC  at ASCO,2015-05-31 09:41:00-04:00,EXEL,positive
468990.0,Exelixis Reports Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for Advanced Melanoma at ASCO,2015-05-30 09:26:00-04:00,EXEL,positive
468991.0,Stifel Talks 5 Biotech Stocks,2015-05-14 12:17:00-04:00,EXEL,neutral
468993.0,Biotech Investors: May 29th Could Be A Big Day,2015-04-21 14:39:00-04:00,EXEL,neutral
468995.0,Morning Market Gainers,2015-04-09 09:45:00-04:00,EXEL,neutral
468996.0,Exelixis Says it Expects Top Line Trail Results in Q2 2015,2015-04-09 08:32:00-04:00,EXEL,positive
468997.0,Exelixis' Cabozantinib Given Fast Track Designation By FDA For Renal Cell Carcinoma,2015-04-09 08:30:00-04:00,EXEL,neutral
468998.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,EXEL,neutral
468999.0,Exelixis Spikes Higher,2015-03-02 12:47:00-05:00,EXEL,neutral
469000.0,"Exelixis Reports Q4 Inline EPS -$0.30, Sales $7.35M Vs Est $7.80M",2015-02-24 16:20:00-05:00,EXEL,neutral
469001.0,Morning Market Gainers,2015-02-19 09:46:00-05:00,EXEL,neutral
469002.0,Benzinga's Top #PreMarket Gainers,2015-02-19 08:13:00-05:00,EXEL,positive
469003.0,Roche's Genentech Announces FDA Grants Cobimetinib Priority Review for Use in Combination with Zelboraf  in Advanced Melanoma,2015-02-19 04:47:00-05:00,EXEL,positive
469004.0,Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma,2015-02-19 02:05:00-05:00,EXEL,positive
469005.0,Exelixis Says Cabozantinib Could be a Franchise Unto Itself,2015-02-11 11:50:00-05:00,EXEL,neutral
469006.0,Option Alert: Exelixis Feb $2.5 Call; 2000 Contract Trade at Ask @$0.15; Now $2.36,2015-02-11 11:36:00-05:00,EXEL,positive
469007.0,Exelixis Data Release Upcoming; Options Activity Spiking,2015-02-05 15:37:00-05:00,EXEL,neutral
469008.0,"Notable Option Activity For January 28: MDR, STLD, JD, EXEL, MTW, CRUS",2015-01-28 15:40:00-05:00,EXEL,neutral
469009.0,Option Alert: Exelixis May $2 Call; 1790 Contract Trade at Ask @$0.55; Now $2.00,2015-01-28 13:25:00-05:00,EXEL,positive
469010.0,UPDATE: Exelisxis Spokesperson Says Co has Already Stated They are Seeking Partner for Cabozantinib in RCC ex-U.S.; But have Not Announced Anything,2015-01-28 11:27:00-05:00,EXEL,neutral
469011.0,"Exelixis Spokesperson Says No News Released Today; Says Roche Reported this Morning, and There Were Several Mentions of Cobimetinib, The Partnered Program",2015-01-28 11:25:00-05:00,EXEL,negative
469012.0,Option Alert: Exelixis May $3 Call; 1198 Contract Trade at Ask @$0.30; Now $1.98,2015-01-28 10:57:00-05:00,EXEL,positive
469013.0,"Najarian Says Exelixis Could be Next Ziopharm, Intrexon-type Runner, Based on Call Activity",2015-01-28 10:48:00-05:00,EXEL,neutral
469014.0,Option Alert: Exelixis May $2 Call; 7818 Contract Trade at Ask @$0.40; Now $1.88,2015-01-28 10:37:00-05:00,EXEL,positive
469015.0,"Option Alert: Exelixis Jan $2 Call; 1,089 Contract Trade at Ask @$0.10; Currently $1.89",2015-01-08 10:35:00-05:00,EXEL,positive
469016.0,"Exelixis, Swedish Orphan Biovitrum AB (Sobi) Extend And Restructure Distribution Agreement for COMETRIQ",2015-01-07 08:33:00-05:00,EXEL,positive
469017.0,19 Lesser-Known Biotech Stocks With Robust Drug Pipelines,2014-12-31 08:59:00-05:00,EXEL,positive
469018.0,Genentech Submits NDA to FDA for Cobimetinib Used in Combination With Zelboraf in Advanced Melanoma,2014-12-15 05:11:00-05:00,EXEL,positive
469019.0,Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip,2014-12-01 13:43:00-05:00,EXEL,positive
469020.0,"Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol",2014-12-01 10:23:00-05:00,EXEL,negative
469021.0,Morning Market Losers,2014-12-01 09:53:00-05:00,EXEL,negative
469022.0,Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib; Did Not Meet Primary Endpoint,2014-12-01 08:03:00-05:00,EXEL,neutral
469023.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,EXEL,neutral
469024.0,"Exelixis Announces Positive Preliminary Data from Investigator-Sponsored Phase 1 Trial of XL888, Vemurafenib",2014-11-16 07:04:00-05:00,EXEL,positive
